ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors
Clinical Pharmacology & Therapeutics
◽
10.1016/j.clpt.2005.12.034
◽
2006
◽
Vol 79
(2)
◽
pp. P10-P10
◽
Cited By ~ 2
Author(s):
F GUO
◽
S LETRENT
◽
D NOE
◽
A QIN
◽
K ROHRBACHER
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Kinase Inhibitor
◽
Her2 Positive
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Related Documents
Cited By
References
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-007-0427-6
◽
2007
◽
Vol 60
(6)
◽
pp. 799-809
◽
Cited By ~ 8
Author(s):
Feng Guo
◽
Stephen P. Letrent
◽
Amarnath Sharma
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Population Pharmacokinetics
◽
Solid Tumors
◽
Kinase Inhibitor
◽
Her2 Positive
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
PII-70A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors
Clinical Pharmacology & Therapeutics
◽
10.1016/j.clpt.2005.12.195
◽
2006
◽
Vol 79
(2)
◽
pp. P54-P54
Author(s):
F GUO
◽
S LETRENT
◽
A SHARMA
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Kinase Inhibitor
◽
Population Pharmacokinetic Analysis
◽
Pharmacokinetic Analysis
◽
Population Pharmacokinetic
◽
Her2 Positive
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
Cancer Chemotherapy and Pharmacology
◽
10.1007/s00280-007-0579-4
◽
2007
◽
Vol 62
(1)
◽
pp. 97-109
◽
Cited By ~ 10
Author(s):
Feng Guo
◽
Stephen P. Letrent
◽
Pamela N. Munster
◽
Carolyn D. Britten
◽
Karen Gelmon
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Clinical Characteristics
◽
Kinase Inhibitor
◽
Her2 Positive
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
10.1158/0008-5472.sabcs-09-5060
◽
2009
◽
Cited By ~ 18
Author(s):
T. Hickish
◽
D. Wheatley
◽
N. Lin
◽
L. Carey
◽
S. Houston
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Metastatic Breast
◽
Her2 Positive
◽
Bibw 2992
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Cancer Management and Research
◽
10.2147/cmar.s321428
◽
2021
◽
Vol Volume 13
◽
pp. 7165-7174
Author(s):
Ying Sun
◽
Beibei Chen
◽
Jisheng Li
◽
Ling Peng
◽
Shuguang Li
◽
...
Keyword(s):
Breast Cancer
◽
Metastatic Breast Cancer
◽
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Real World
◽
Kinase Inhibitor
◽
Metastatic Breast
◽
Efficacy And Safety
◽
Her2 Positive
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Investigational New Drugs
◽
10.1007/s10637-021-01093-7
◽
2021
◽
Author(s):
Katrina S. Pedersen
◽
Patrick M. Grierson
◽
Joel Picus
◽
A. Craig Lockhart
◽
Bruce J. Roth
◽
...
Keyword(s):
Tyrosine Kinase
◽
Phase I
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Phase I Study
◽
Kinase Inhibitor
Download Full-text
Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-11-2378
◽
2011
◽
Vol 18
(4)
◽
pp. 1092-1100
◽
Cited By ~ 50
Author(s):
Adil I. Daud
◽
Smitha S. Krishnamurthi
◽
Mansoor N. Saleh
◽
Barbara J. Gitlitz
◽
Mitesh J. Borad
◽
...
Keyword(s):
Tyrosine Kinase
◽
Phase I
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Phase I Study
◽
Kinase Inhibitor
◽
Advanced Solid Tumors
◽
Abl Tyrosine Kinase
◽
Abl Tyrosine Kinase Inhibitor
Download Full-text
Abstract A108: A phase I and pharmalogical study of the broad‐spectrum tyrosine kinase inhibitor JNJ‐26483327, administered to subjects with advanced or refractory solid tumors
10.1158/1535-7163.targ-09-a108
◽
2009
◽
Author(s):
Inge R. Konings
◽
Maja J. de Jonge
◽
Herman Burger
◽
Ate van der Gaast
◽
Ludy EC van Bijsterveld
◽
...
Keyword(s):
Tyrosine Kinase
◽
Phase I
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Broad Spectrum
◽
Kinase Inhibitor
Download Full-text
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Cancer Research and Treatment
◽
10.4143/crt.2017.303
◽
2018
◽
Vol 50
(3)
◽
pp. 835-842
◽
Cited By ~ 24
Author(s):
Tae Min Kim
◽
Keun-Wook Lee
◽
Do-Youn Oh
◽
Jong-Seok Lee
◽
Seock-Ah Im
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Solid Tumors
◽
Kinase Inhibitor
◽
Phase 1
◽
Advanced Solid Tumors
Download Full-text
Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714
Toxicological Sciences
◽
10.1093/toxsci/kfp033
◽
2009
◽
Vol 108
(2)
◽
pp. 492-500
◽
Cited By ~ 55
Author(s):
Bo Feng
◽
Jinghai J. Xu
◽
Yi-An Bi
◽
Rouchelle Mireles
◽
Ralph Davidson
◽
...
Keyword(s):
Tyrosine Kinase
◽
Tyrosine Kinase Inhibitor
◽
Kinase Inhibitor
◽
Hepatic Transporters
◽
Her2 Tyrosine Kinase Inhibitor
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close